News coverage about Atossa Genetics (NASDAQ:ATOS) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Atossa Genetics earned a coverage optimism score of 0.22 on Accern’s scale. Accern also gave media coverage about the company an impact score of 46.218436055337 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Atossa Genetics (NASDAQ ATOS) traded down 2.5810% during trading on Wednesday, hitting $0.3699. 55,978 shares of the company’s stock traded hands. The stock’s market cap is $2.74 million. The firm’s 50-day moving average price is $0.44 and its 200 day moving average price is $0.86. Atossa Genetics has a 12-month low of $0.32 and a 12-month high of $4.20.

WARNING: “Atossa Genetics (NASDAQ:ATOS) Receives Coverage Optimism Score of 0.22” was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.dailypolitical.com/2017/08/09/atossa-genetics-nasdaqatos-receives-coverage-optimism-score-of-0-22.html.

Atossa Genetics Company Profile

Atossa Genetics Inc is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company’s leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts.

Insider Buying and Selling by Quarter for Atossa Genetics (NASDAQ:ATOS)

Receive News & Ratings for Atossa Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.